Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function.

ABSTRACT:

Background & aims

Di-alpha hydroxy bile salt, sodium chenodeoxycholate (CDC), and bile acid binding have unclear effects on colonic transit in health and disease.

Methods

We performed 2 randomized, double-blind, placebo-controlled studies. In healthy volunteers (20 per group), we evaluated the effects of oral placebo, 500 mg, or 1000 mg of CDC (delayed-release, each given for 4 days) on gastrointestinal and colonic transit. A second trial compared the effects of colesevelam (1.875 g, twice daily) versus placebo in 24 patients (12 per group) with diarrhea-predominant irritable bowel syndrome (IBS-D) on transit, daily bowel frequency and consistency, and colonic mucosal permeability. Serum fasting 7alpha-hydroxy-4-cholesten-3-one (7alphaC4) was measured to screen for bile acid

SUBMITTER: Odunsi-Shiyanbade ST 

PROVIDER: S-EPMC2822105 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature